Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.
Dr. Kurre's laboratory has longstanding expertise in Fanconi Anemia (FA), a genetic condition with prominent hematologic complications. With training in transplantation and hematopoietic stem cell biology, he hopes to improve the understanding of the progressive hematopoietic failure in patients with bone marrow failure and FA, broaden diagnostic approaches, and develop next generation therapies.
Where Discovery Leads is a multimedia storytelling project that delves into key research themes at CHOP Research Institute. This is part two of a three-part series that focuses on novel diagnostic tools and approaches being developed under the leadership of the Center for Autism Research at CHOP. See part 1 and part 3 of this series.
Research in the Brodeur Lab focuses on two main areas: nanoparticle drug delivery and cancer predisposition. Nanomedicines allow the delivery of much more drug to the tumor and much less to the patient. The lab is also interested in identifying novel cancer predisposition genes as well as developing enhanced surveillance techniques to identify cancer early in predisposed individuals, improve outcomes, and reduce side effects.